In agreement with this hypothesis, knocking-out CRT in tumors with induced C/EBP-β LIP completely abrogated the doxorubicin-induced ICD and reduced doxorubicin anti-tumor efficacy, indicating that both C/EBP-β LIP and CRT are necessary for a full rescue of doxorubicin efficacy in resistant tumors. Here, CEBPB is linked to neoplasm.